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Abstract: Ammonium trichloro[1,2-ethanediolato-O,O']-tellurate (AS101) is the most 
important synthetic Te compound from the standpoint of its biological activity. It is a 
potent immunomodulator with a variety of potential therapeutic applications and 
antitumoral action in several preclinical and clinical studies. An experimental design has 
been used to develop and optimize a novel microwave-assisted synthesis (MAOS) of the 
AS101. In comparison to the results observed in the literature, refluxing Te(IV) chloride 
and ethylene glycol in acetonitrile (Method A), or by refluxing Te(IV) chloride and 
ammonium chloride in ethylene glycol (Method B), it was found that the developed 
methods in the present work are an effective alternative, because although performance 
slightly decreases compared to conventional procedures (75% vs. 79% by Method A, and 
45% vs. 51% by Method B), reaction times decreased from 4 h to 30 min and from 4 h to 
10 min, by Methods A and B respectively. MAOS is proving to be of value in the rapid 
synthesis of compounds with new and improved biological activities, specially based on 
the benefit of its shorter reaction times.  
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Tellurium (Te), discovered in 1783, is one of the least abundant elements in the earth’s lithosphere 
and it is one of the five elements that has never been reported in sea water. However, it is the fourth 
most abundant trace element in the human body, and is unusually abundant in human food [1]. The 
investigation of therapeutic activities of Te compounds is rather limited in literature, despite the 
relative abundance of Te in the human body [2–4]. The similarity of selenium and Te encompasses not 
only their names and positions on the periodic table but, to a large degree, their chemistry and 
biochemistry. Also, similar to Se 40 years ago, it is possible that the toxic element Te will ultimately 
be found to be an essential element [5].  
Te chemistry has made great progress in the last few years [6]. Obtention of inorganic and organic 
Te compounds, as well as their use as reagents to perform specific organic manipulations and 
synthesis, have been well reviewed in literature, demonstrating Te compounds as a powerful tool in a 
broad range of organic chemical manipulations, often characterized by their selective behaviour [7,8]. 
Ammonium trichloro[1,2-ethanediolato-O,O']-tellurate (AS101) is the most important synthetic Te 
compound from the standpoint of its biological activity. It is a potent immunomodulator with a variety 
of potential therapeutic applications and antitumoral action presently being investigated in several 
preclinical and clinical studies [9]. AS101 has also been shown to possess antibacterial ability [10,11], 
antioxidative properties [12], mediates anti-inflammatory and anti-apoptotic effects [13,14], protects 
from chemotherapy-induced bone marrow toxicity and alopecia [15], restores dopaminergic neurons in 
Parkinson’s disease models [16] and may be useful as a treatment for type 2 diabetes [17], multiple 
sclerosis [18], premature ovarian failure in cancer treatments [19], atopic dermatitis [20] and in clinical 
immunosuppression conditions involving AIDS [21] and West Nile virus [22]. 
Over recent years, heating and driving chemical reactions by microwave (MW) energy has been a 
significant interest in the scientific community, in particular applied to microwave-assisted organic 
synthesis (MAOS), medicinal chemistry, drug discovery and polymer science. Some excellent reviews 
and books are present in the literature [23–32]. In summary, the capacity of microwaves to couple 
energy directly to the material is the primary advantage of MW processing as compared to 
conventional techniques, allowing shorter reaction times, uniform heating, higher yields and often 
enhancing material properties and product purities by reducing unwanted side reactions. Moreover, the 
combination of solid supported reagents and scavengers, polymer supported reactions, solvent free 
conditions and MAOS methodologies, has several advantages in the ecofriendly approach termed 
green chemistry [33–36]. 
MAOS is proving to be instrumental in the rapid synthesis of compounds with new and improved 
biological activities. The extensive use of MW irradiation for the synthesis of molecules of 
pharmacological interest has contributed to improve the access to different chemical scaffolds by 
applying new methodologies and techniques, specially based on the benefits related to better yields and 
shorter reaction times. Clearly MW irradiation is becoming a fundamental tool for optimizing key 
steps in the synthesis of target compounds within the field of drug discovery [23,33,34,37,38]. 
Continuing with our studies on MAOS [39–43], we draw attention to the AS101 compound. The 
main objective of the present paper was to develop an optimized a method for MW assisted synthesis 
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of AS101. To achieve this objective, independent variables such as MW power, pressure, synthesis 
temperature and time of the reaction on AS101 obtention were examined. 
2. Results and Discussion 
AS101 was previously synthesized by refluxing Te(IV) chloride and ethylene glycol in acetonitrile 
as shown in Scheme 1 (Method A), or by refluxing Te(IV) chloride and ammonium chloride in 
ethylene glycol (Method B) [44]. A number of very interesting syntheses have been performed 
omitting the solvent from the reaction and a majority of the publications contain work conducted in 
this manner. Further, the solventless microwave-assisted reaction is now gaining popularity as it 
provides an opportunity to work with open vessels, thus avoiding the risk of high pressure 
development and with a possibility of upscaling the reactions on preparative scale [27,45]. As a first 
approach, the reactants were irradiated at 120 °C under solvent-free conditions. However, only 
decomposition of the reaction mixture was achieved. Thus, the reactions (Method A and Method B) 
were checked in the presence of solvent. 
Scheme 1. Synthesis of AS101. 
 
Both methods have been optimized using experimental designs: Plackett–Burman (PB) and central 
composite (CC). PB allows the unbiased estimation of all the main effects for all variables, requiring 
few experiments. The examined factors and their levels are presented in Table 1. PB requires that the 
frequency of each level of a variable should be equal and that in each test the number of high and low 
variables should also be equal. Then, the effects of changing the other variables cancel each other out, 
while determining the effect of any particular variable.  
Table 1. Factor levels in the Plackett–Burman design for MAOS AS101 synthesis. 
 Key High level (+) Low level (−) Unit 
Method A     
Power X1a 90 50 watt 
Pressure X2a 7 3 bar 
Time X3a 30 10 minute 
Method B     
Power X1b 80 50 watt 
Temperature X2b 120 80 °C 
Time X3b 20 10 minute 
Although MAOS and its applications have undergone rapid growth over the last decade, the 
technology is not yet employed routinely in all synthetic laboratories. A significant obstacle to 
implementation concerns the empirical work required to adapt established conditions into alternatives. 
However, experimental designs and statistical analysis of a designed set of experiments allows for 
much more data to be obtained than is normally the case with the one variable at a time approach [46]. 
Int. J. Mol. Sci. 2014, 15 3290 
 
 
Table 2 summarizes the design matrix and the AS101 yield obtained in each of the experiments; the 
results are expressed as percentages. Experiments based on Method A, displayed the best AS101 
yielding rates (53.00% ± 1.4% to 78.5% ± 0.7%) in comparison with Method B (20.00% ± 4.2% to 
45.00% ± 0.3%). 
The numerical analysis of the results given in the recovery column of Table 2, were evaluated by an 
ANOVA test (Table 3) and the effects were visualized using the Pareto chart shown in Figure 1.  
Table 2. Design matrix and response values in Plackett–Burman factorial design for 
MAOS AS101 synthesis. 
 X1a X2a X3a X1b X2b X3b Yield Method A Yield Method B 
1 + + + + − − 73.5 ± 2.1 20.0 ± 4.2 
2 − + + − + − 78.5 ± 0.7 34.5 ± 2.1 
3 − − + + − + 67.0 ± 2.8 38.0 ± 5.7 
4 + − − + + − 53.0 ± 1.4 45.0 ± 0.3 
5 − + − + + + 78.5 ± 0.7 36.5 ± 0.7 
6 + − + − + + 75.5 ± 0.7 31.0 ± 2.8 
7 + + − − − + 53.0 ± 1.4 33.0 ± 1.4 
8 − − − − − − 0 0 
Method A: X1a (power), X2a (pressure) and X3a (time); Method B: X1b (power), X2b (temperature) and X3b (time). 
On Pareto charts, the bar length is proportional to the absolute value of the estimated main effect 
and a vertical reference line corresponding to 95% confidence interval is included. An effect is 
significant if it exceeds this reference line while a positive or negative sign means that the response is 
enhanced or reduced, respectively.  
Equations (1) and (2) describing the empirical relationship between the independent variables and 
response were generated and are given underneath: 
AS101 (Yield in % by Method A) = 5.83703 + 0.272984 X1a + 3.70453 X2a + 2.41162 
X3a + 0.0136094 X1a X2a − 0.0152844 X1a X3a − 0.100406 X2a X3a 
(1)
AS101 (Yield in % by Method B) = −208.317 + 3.04337 X1b + 1.59551 X2b + 8.25513 
X3b − 0.0177771 X1b X2b − 0.081125 X1b X3b − 0.0311937 X2b X3b 
(2)
The magnitude and direction of the factor coefficient in the generated equations explains the nature 
of the effect of factors on the AS101 yield. The R2 values obtained were 0.9779 and 0.8394 for 
methods A and B respectively. R2 value gives a measure of how much variability in the observed 
response can be explained by the experimental parameters and their interactions. When expressed as a 
percentage, it implies that a total variation of 97.79% in AS101 yield obtained by Method A can be 
attributed to the independent variables and only 2.20% cannot be ascribed to them. The predicted R2 
values are in acceptable agreement with the adjusted R2 of 0.9632 and 0.7324 for Methods A  
and B respectively. 
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Figure 1. Standardised (p = 95%) main effects Pareto charts for the Plackett–Burman 
desing for the different variables studied and graphs of main effects in AS101 yields by 
Method A (A) and by Method B (B).  
 
The ANOVA results are given in Table 3. The p value serves as a tool for checking the significance 
of each of the coefficients and is indicative of the interaction strength of each independent variable. 
Low values of p ˂ 0.05 indicate high significance of the corresponding coefficients. 
Table 3. Design matrix and response values in Plackett–Burman factorial design. 
Source Sum of squares df Mean square F value  p value Prob ˃ F 
X1a 7.99 1 7.99 1.57 0.2452 
X2a 449.122 1 449.122 88.36 ˂0.0001 
X3a 1128.12 1 1128.12 221.94 ˂0.0001 
X1a* X2a 4.74 1 4.74 0.93 0.3624 
X1a* X3a 149.51 1 149.51 29.41 ˂0.0001 
X2a* X3a 64.52 1 64.52 12.69 0.0074 
Total error 40.66 8 5.08   
Cor total 1846.32 15    
X1b 8.57 1 8.57 0.29 0.6048 
X2b 4.98 1 4.98 0.17 0.6921 
X3b 7.54 1 7.54 0.26 0.6269 
X1b* X2b 455.07 1 455.07 15.40 0.0044 
X1b* X3b 592.31 1 592.31 20.05 0.0021 
X2b* X3b 155.68 1 155.68 5.27 0.0505 
Total error 236.35 8 29.54   
Cor total 1472.22 15    
Method A: X1a (power), X2a (pressure) and X3a (time); Method B: X1b (power), X2b (temperature) and X3b (time). 
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A response surface methodology (RSM) using a central composite were generated by varying the 
levels of two factors while keeping the third one constant (Figure 2). Pressure, time and power were 
choosen as the base factors with increments of 0.2 bar, 1 min and 1 watt respectively. 
Figure 2. Response-surface graphs representing: the effect of power, pressure and time on 
the AS101 yield by Method A (A) and relative effect of time; temperature and power on 
the AS101 yield by Method B (B). 
 
For Method A, according to the design of experiments and the results obtained, it was determined 
that the optimum reaction conditions were 50 watts, 7 bar and 30 min. Subsequent experiments were 
expanded and the pressure time up to 9 bar and 50 min but previously obtained results were not 
improved. Reactions were also performed in three stages of 10 min each, removing the HCl produced 
in the reaction to improve the yield with no positive results. As variables that positively affect the 
reaction are the pressure and time, the combined effect is negative for the reaction, but significantly 
lower than the positive effect that both generate. In relation to results observed in the literature, as [44] 
observed a 4 h and 30 min reaction with a yield of 75% to 79%, it can therefore be concluded that the 
MAOS of AS101 using Method A is more effective compared to alternative conventional procedure. 
For Method B, the optimum reaction conditions were 80 watts, 80 °C and 10 min of reaction. 
Further experiments were made to increase the power to 120 watts without improving the results 
previously obtained. Likewise AS101 synthesis performed using Method B with the experiment in a 
closed tube, did not provide satisfactory results. The reaction did not start to occur until after 2–3 min, 
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at which time the pressure began to increase and control was lost. Power is the variable that positively 
affects the reaction, but negligible weight was evident, also in subsequent experiments. We can 
conclude therefore that this method does not fit as well to the statistical parameters studied as Method 
A. It is not as reproducible and generates a lot of noise in the system. In relation to results observed in 
the literature, as [44] found a 4 h and 10 min reaction with a yield of 51% to 45%, it can be concluded 
that the MAOS of AS101 by Method B is more effective, because although performance decreases 
compared to the conventional procedure by 6%, it took 95% less time. 
3. Experimental Section  
3.1. General Experimental Procedure 
All the chemical reagents used were purchased from Sigma Chemical Co. (St. Louis, MO, USA) 
and were of analytical grade. MAOS was performed in an Emrys Creator® single-mode microwave 
cavity producing controlled irradiation at 2.45 GHz (Biotage AB, Uppsala, Sweden). The reaction 
times refer to the hold times at the temperature indicated. The temperature was monitored with an  
IR sensor equipped on the outside of the reaction vessel. Two procedures for AS101 obtention  
were performed. Samples of AS101 are available from the authors. 
3.1.1. AS101 Obtention by Method A 
TeCl4 (0.675 g) and ethylene glycol (0.387 g) were dissolved in acetonitrile (5 mL). The mixture 
was MW irradiated for 30 min at 50 W. On cooling the reaction mixture, a white crystalline  
solid is obtained, washed with acetonitrile, filtered and vacuum dried. The solid (615 mg, 79%) was  
identified as: 
Found (%): C, 7.70; H, 2.58; N, 4.49. C2H8Cl3NO2Te.  
Calculated (%): C, 7.85; H, 2.37; N, 4.42.  
IR (Golden-Gate): v = 3183 (NH): 1390 (NH4+): 1019: 894 cm−1.  
NMR-1H (DMSO-d6, δ, ppm): 4.36 (s, 4H, CH2): 7.16 (t, 4H, J = 50 Hz, NH4+).  
NMR-13C (DMSO-d6, δ, ppm): 68.13.  
EM (m/z): 292 (M+-NH4,1), 290 (M
+–NH4
+,1), 260 (M+–NH4
+–Cl [Te130, 2Cl35],7),  
258 (M+–NH4
+–Cl [Te128, 2Cl35],13), 256 (M
+–NH4
+–Cl [Te126, 2Cl35],13), 254 (9), 224 (42),  
223 (35), 221 (19), 200 (36), 198 (27), 196 (14), 190 (69), 188 (63), 186 (37), 165 (21), 163 (18), 
161 (11), 146 (5), 130 (25), 128 (23), 126 (13). 
3.1.2. AS101 Obtention by Method B 
TeCl4 (1.35 g) and NH4Cl (0.387 g) were dissolved in ethylene glycol (5 mL). The mixture was 
MW irradiated for 10 min at 80 W. On cooling the reaction mixture, a white crystalline  
solid is obtained, washed with acetonitrile, filtered and vacuum dried. The solid (706 mg, 45%) was  
identified as: 
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Found (%): C, 7.81; H, 2.33; N, 4.45. C2H8Cl3NO2Te.  
Calculated (%): C, 7.70; H, 2.58; N, 4.49.  
IR (Golden-Gate): 3198 (NH): 1399 (NH4+): 1017: 889 cm−1.  
NMR-1H (DMSO-d6, δ, ppm): 4.36 (s, 4H, CH2): 7.16 (s, 4H, NH4+).  
NMR-13C (DMSO-d6, δ, ppm): 68.10.  
EM (m/z): 292 (M+–NH4
+,1), 290 (M+–NH4
+ ,1), 260 (M+–NH4
+–Cl [Te130,2Cl35], 11),  
258 (M+–NH4
+–Cl [Te128, 2Cl35],20), 256 (M
+–NH4
+–Cl [Te126, 2Cl35],21), 254 (14), 224 (52),  
223 (43), 221 ( 23), 200 (46), 198 (36), 196 (18), 190 (100), 188 (92), 186 (54), 165 (27), 163 (23), 
161 (14), 146 (7), 130 (32), 128 (30), 126 (18). 
3.2. 1H-NMR and 13C-NMR Analysis 
1H-NMR and 13C-NMR analyses were performed on Varian Mercury 300 (300 MHz for 1H) 
instrument (Agilent Technologies®, Palo Alto, CA, USA), equipped with a 5 mm probe. Each obtained 
product, was dissolved in 400 μL of DMSO-d6, (Sigma-Aldrich
®, Madrid, Spain) shaken in a vortex 
mixer, and the resulting mixture was placed into a 5-mm diameter ultra-precision NMR sample tubes 
(Norell®, Landisville, PA, USA). The temperature of the sample in the probe was 30 °C. The chemical 
shifts are reported in ppm, using the solvent proton signal as standard. The area of the signals was 
determined by using the equipment software, and the integrations were carried out three times to 
obtain average values. All figures of the 1H-NMR spectra plotted at a fixed value of absolute intensity 
to be valid for comparative purposes. 13C-NMR analysis was performed at 189 MHz for 13C. The same 
samples subjected to 1H-NMR were used for 13C-NMR. 
3.3. MS Analysis 
A Finnigan™ TRACE™ DSQ™ (Thermo Electron Corporation, Austin, TX, USA) quadrupole 
mass spectrometer and a direct sample probe fitted with a direct exposure probe was used for sample 
introduction and analysis. Mass spectra were recorded in electron impact (EI) mode at an  
ionization voltage of 70 eV. Data were collected and processed by Xcalibur™ software package 
(Thermo Finnigan, Austin, TX, USA). 
3.4. Infrared Spectroscopy (FTIR) 
Spectra were recorded using an ABB Bomem MB 102 spectrometer (ABB-Bomem Inc., Quebec 
City, QC, Canada). By means of a single reflection diamond ATR accessory (Specac Inc.: Swedesboro, 
NJ, USA). The samples were previously dried overnight under reduced pressure and homogenized by 
grinding. The frequency value of each band was obtained automatically by the software. 
3.5. Optimization of MAOS AS101 Procedure 
A Plackett–Burman (PB) design was used to evaluate the influence of factors involved in the 
MAOS of AS101 procedure in a reduced number of runs for the two methods (A and B) considered in 
this study. The total number of experiments to be carried out is K + 1, where K is the number of 
variables. Each variable is represented at two levels, high and low denoted by (+) and (−) respectively. 
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The main effect of each variable on AS101 yield was calculated as the difference between the average 
of measurements made at high (+1) and low (−1) levels setting, by using the following equation: 
E(Xi) = ∑Y(+)i − ∑Y(−)i/N (3)
Y(+)i and Y(−)i are the AS101 yield from the experimental runs in which the variables being tested are 
considered at their maximum and minimum levels respectively and N is the half number of 
experiments carried out. When E(Xi) is positive, the influence of the variable is greater at the high 
concentration, and when it is negative, the influence of the variable is greater at the low concentration. 
Subsequently, a composite central design was set up for the optimization of significant experimental 
factors, analyzing the individual response and then applying the above mentioned desirability function. 
The obtained models of the regression were validated and analyzed using the analysis of  
variance (ANOVA).  
3.6. Statistical Analyses 
For experimental design modelling, programs from Statgraphics Plus 4.0 routine (Statgraphics 
Graphics Corporation, STSC, Rockville, MD, USA) were used. 
4. Conclusions  
In summary, microwave-assisted organic synthesis has proven to be a useful tool for the obtention 
of the immunomodulator organotellurium compound, ammonium trichloro(dioxoethylene-O,O')tellurate 
(AS101). Two easy, efficient and fast procedures for syntheses of AS101 were developed since the 
reaction took place in only 30 min with a yield of 79% (Method A) and 10 min with a yield of 45% 
(Method B); and by conventional heating, 4 h are necessary with a 75% yield (Method A) and 51% 
yield (Method B). We believe that the proposed procedure has the potential to evolve to incorporate 
new processes for obtaining AS101 derivatives, since the optimization of newly discovered lead 
compounds relies upon the advancement of synthetic technologies.  
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